Skip to main content

LabCorp Injects $2M into SynapDx for Autism Test Development

NEW YORK (GenomeWeb News) – Laboratory Corporation of America is investing $2 million in SynapDx to further its development of an autism spectrum disorder test.

The investment, announced today by SynapDx, follows a $6 million Series A1 funding round completed in December to support the Lexington, Mass.-based firm's clinical study in support of the ASD test, which is intended to help physicians identify children with ASD earlier than they can today.

The test would be the first step in SynapDx's plans to build a broader menu of pediatric neurodevelopment tests, the company said.

"LabCorp and SynapDx have a shared vision about the future of diagnostics," SynapDx CEO Stanley Lapidus said in a statement. "The investment is validation of LabCorp's commitment to innovation and SynapDx's transformational approach to autism diagnostics."

SynapDx's blood-based test is being developed to measure RNA expression in order to differentiate children with a higher risk for ASDs from those with a lower risk. Its aim is to identify children with ASD by the age of 36 months.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.